Niu X, et al. - The upshot of 7 intracoronary agents (adenosine, anisodamine, diltiazem, nicorandil, nitroprusside, urapidil, and verapamil) on the no-reflow phenomenon was explored by the authors in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Findings brought to light the possibility of an improvement in the myocardial reperfusion, cardiac function, and clinical outcomes through the intracoronary administration of anisodamine in the study cohort.